Daniel A. Moros - Concepedia

Author

Daniel A. Moros

Also Known As

D A Moros, D MOROS, D Moros, D. A. Moros, D. Moros, DANIEL A. MOROS, DANIEL MOROS, Daniel A Moros, Daniel A. Moros, Daniel Moros

Publications

311

Citations

H-Index

Concepts

All Affiliations

Taro Pharmaceuticals (United States)Icahn School of Medicine at Mount Sinai Albert Einstein College of Medicine Mount Sinai Medical Center Hebrew University of Jerusalem

About

Daniel A. Moros is an author at Taro Pharmaceuticals (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	98
2	Pharmacology	3	3	49
3	Obstetrics	1	1	18
4	Pulmonary Disease	1	1	31
5	Pulmonary Medicine	1	1	31

Daniel A. Moros

Publications

230

Citations

H-Index

Page 1

	Year	Citations
Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline) Melvin D. Yahr, MARINA R. MENDOZA, Daniel A. Moros, Acta Neurologica Scandinavica	1983	36
Respiratory dysfunction due to L-Dopa therapy for parkinsnism: Diagnosis using serial pulmonary function tests and respiratory inductive plethysmography Henry M. Zupnick, Lee K. Brown, Albert Miller, The American Journal of Medicine AsthmaPulmonary CareRespiratory TherapyRespiratory DysfunctionPulmonary Physiology	1990	31
Criteria to Assess In Vivo Performance and Bioequivalence of Generic Controlled‐Release Formulations of Carbamazepine Meir Bialer, Avi Yacobi, Daniel A. Moros, Epilepsia	1998	22
Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine Meir Bialer, Lidia Arcavi, Sherbel Sussan, Epilepsy Research Pharmaceutical SciencePharmacological StudyMedicinePharmacotherapyNew Criteria	1998	21
Who Needs Individual Bioequivalence Studies for Narrow Therapeutic Index Drugs? A Case for Warfarin Avraham Yacobi, Eric Masson, Daniel A. Moros, The Journal of Clinical Pharmacology	2000	21
Selegiline in the treatment of Parkinson's disease - long term experience Melvin D. Yahr, T. S. Elizan, Daniel A. Moros Acta Neurologica Scandinavica	1989	19
Human transplacental transfer of carbidopa/levodopa C. Merchant, G. Cohen, Catherine Mytilineou, Journal of Neural Transmission - Parkinsons Disease and Dementia Section XenotransplantationFertilityGynecologyHuman Transplacental TransferMaternal-fetal Medicine	1995	18
The effect of guanethidine on ouabain-induced ventricular arrhythmia in the cat. A Raines, Daniel A. Moros, Barrie Levitt PubMed MedicinePhysiologyArrhythmiaCardiovascular PharmacologyOuabain-induced Ventricular Arrhythmia	1968	18
A multiple-dose safety and bioequivalence study of a narrow therapeutic index drug: A case for carbamazepine Avraham Yacobi, Steve Zlotnick, John L. Colaizzi, Clinical Pharmacology & Therapeutics	1999	17
Treatment of essential tremor with the barbiturate t2000 (1,3‐dimethoxymethyl‐5,5‐diphenyl‐barbituric acid) Calvin Melmed, Daniel A. Moros, Howard Rutman Movement Disorders	2007	17

Page 1